Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.69 |
| ▸ | USP2 | O75604 | 10/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656183 | 0.82 | CYP2D6 (0.55) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL10047375 | 0.82 | NPSR1 (0.61) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL30490313 | 0.80 | CYP3A4 (0.81) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL71724 | 0.79 | NPSR1 (0.57) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL15797515 | 0.79 | NPSR1 (0.57) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL1121779 | 0.79 | CYP3A4 (0.51) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL9359082 | 0.79 | NPSR1 (0.57) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL2337932 | 0.77 | CYP2D6 (0.65) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL8175607 | 0.77 | OPRM1 (0.78) | CYP2D6NPSR1CYP2C19OPRM1CHRM2 | |
| SCHEMBL10716169 | 0.77 | CYP2D6 (0.58) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751118-B1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2751118-B1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2751118-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8664213-B2 | Spiro bicyclic diamine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664213-B2 | Spiro bicyclic diamine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664213-B2 | Spiro bicyclic diamine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130231324-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-05 | — | — | US | disclosed |
| US-20130231324-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-05 | — | — | US | disclosed |
| US-20130231324-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-05 | — | — | US | disclosed |
| WO-2013033059-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033059-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231324-A1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | CD4, SELE, VCAM1 | CYP3A4 740/4885CYP2D6 381/4885USP2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.